Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP)

Although nivolumab is known to cause immune-related interstitial lung diseases (ILD), the detailed characteristics of ILD are still not fully understood. A 68-year-old man was treated with nivolumab because of unresectable sinonasal melanoma, he achieved a complete response soon after the initiation...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Intern Med
Egile Nagusiak: Ishiwata, Tsukasa, Ebata, Takahiro, Iwasawa, Shunichiro, Matsushima, Jun, Ota, Satoshi, Nakatani, Yukio, Tsushima, Kenji, Tada, Yuji, Tatsumi, Koichiro, Takiguchi, Yuichi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: The Japanese Society of Internal Medicine 2017
Gaiak:
Case Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5635305/
https://ncbi.nlm.nih.gov/pubmed/28794361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.8271-16
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak